BPC-157 vs TB-500 vs GHK-Cu
Gastric Pentadecapeptide · Thymosin Beta-4 Fragment · Copper-Binding Tripeptide
Here is how these two compounds compare, based on published research, not marketing claims.
BPC-157
Builds new blood vessels at the injury site through growth factor signaling; over 200 published studies, predominantly animal models.
TB-500
Signals the body's repair cells to migrate toward damaged tissue through actin regulation; derived from the parent protein Thymosin Beta-4.
GHK-Cu
Delivers copper to tissue cells and modulates over 4,000 genes involved in collagen production and tissue remodeling; decades of topical cosmetic use.
BPC-157
212 studies
4 human trials
Not FDA-Approved
TB-500
1050 studies
13 human trials
Not FDA-Approved
GHK-Cu
186 studies
4 human trials
Not FDA-Approved
What it does
BPC-157
In animal studies, drives new blood vessel formation at injury sites, one of the body's main repair signals in damaged tissue. A short peptide fragment originally isolated from human stomach juice that, in rodent models, ramps up production of growth factors involved in healing (VEGF, EGF, FGF). The angiogenic effect documented in those animal studies is what underlies the recovery claims that made BPC-157 prominent in athletic and post-surgical contexts. Published human evidence remains essentially absent.
TB-500
Typically a synthetic 4-amino-acid fragment of thymosin beta-4's active region (Ac-SDKP, the first four residues of the 43-amino-acid parent molecule), though commercial products labeled TB-500 vary in actual composition. Marketed as if interchangeable with full-length Tβ4, but the published human research is on the parent peptide, not the fragment. The mechanism described in animal studies (mobilization of repair cells through actin sequestration) is shared, but the evidence base for TB-500 specifically is a fraction of what exists for thymosin beta-4.
GHK-Cu
Delivers copper to skin and tissue cells, where it switches on the genes that build collagen and switches off the ones that drive aging. Naturally produced by the body; levels decline about 60 percent between the 20s and 60s.
How it works
BPC-157
A copy of a small protein the body naturally makes in the stomach. It works by turning up three repair signals (VEGF, EGF, FGF) that tell the body to build new blood vessels. It also nudges the nitric oxide system, which controls blood flow and inflammation. In animal research, the result is the body's own repair process running faster.
TB-500
A copy of a fragment of a natural protein called Thymosin Beta-4. It works on actin, the scaffolding cells use to crawl through tissue. By turning up that scaffolding-rebuild process, the body's repair cells can migrate to where they're needed, and inflammatory signals get dialed down along the way.
GHK-Cu
GHK-Cu binds copper(II) and delivers it to tissue sites where copper-dependent enzymes drive repair: lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defense, cytochrome c oxidase for cellular energy. It also directly modulates gene expression, upregulating collagen production and stem cell recruitment while downregulating the matrix-degrading enzymes that drive aging. The breadth of gene regulation (over 4,000 genes in transcriptomic studies) is unmatched among peptides, but gene expression changes in laboratory studies are not the same as clinical outcomes in humans.
How often
BPC-157
In studies, given as a daily shot under the skin, usually for several weeks at a time. Some studies have looked at oral forms specifically for gut work.
TB-500
In studies, given as a twice-weekly shot under the skin. The compound stays active in the body longer than BPC-157, which is why dosing is less frequent in protocols.
GHK-Cu
Topical application in cosmetic skincare formulations with decades of commercial use history. Injectable form expected to return to legal pharmacy preparation status following the February 2026 HHS announcement. Published human research is topical; no consensus injectable dosing protocol exists in peer-reviewed literature.
How strong
BPC-157
Local. The action concentrates at the injury rather than spreading body-wide.
TB-500
Body-wide. Unlike BPC-157's local action, TB-500's signal works wherever cells are migrating, which is anywhere repair is happening.
GHK-Cu
The widest gap between mechanistic promise and clinical validation of any compound in PSI's library. Over 4,000 genes modulated in transcriptomic analysis (Pickart and Margolina 2018). Topical cosmetic studies show measurable skin improvements. Zero controlled human trials for injectable systemic use. The mechanism is real; the human systemic evidence is not yet there.
Main tradeoff
BPC-157
Strong animal data on tendons and gut healing. Human studies are thin. And one quirk: most of the published research traces back to a single research group, which limits how independent the findings are.
TB-500
Bigger total research base than BPC-157, including more human studies. The catch: most of that broader work is on the parent protein, Thymosin Beta-4, not the TB-500 fragment specifically. The two don't always behave the same way.
GHK-Cu
Topical GHK-Cu shows measurable improvements in skin thickness, elasticity, and fine lines in cosmetic studies. The copper-binding mechanism and gene expression profile are well-characterized across multiple independent research groups. Whether injectable GHK-Cu produces systemic anti-aging effects in humans is not established. Long-term safety of regular injectable administration is not characterized. As a naturally occurring peptide that declines approximately 60% between the 20s and 60s, the theoretical safety profile is favorable, but theoretical safety is not established safety.
Best for
BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
TB-500
- Research on systemic recovery across multiple sites
- Research into a body-wide repair signal rather than a localized one
- Research using twice-weekly dosing
GHK-Cu
- Research interest in copper-peptide mechanisms and broad gene modulation
- Research comparing topical versus systemic delivery of naturally occurring repair peptides
- Research contexts where the gap between transcriptomic promise and clinical validation is the central question
How to choose
A good fit for BPC-157
- Research targeting a specific local injury: tendons, ligaments, or gut lining
- Research focused on angiogenesis (new blood vessel formation) at the injury site
- Research using daily subcutaneous injection protocols
A good fit for TB-500
- Research targeting systemic tissue repair across multiple sites simultaneously
- Research focused on cell migration and actin-mediated repair pathways
- Research interested in the Thymosin Beta-4 repair pathway
A good fit for GHK-Cu
- Research targeting skin aging, collagen decline, or broad gene expression modulation
- Research focused on copper-dependent enzyme activation in tissue remodeling
- Research comparing topical versus systemic delivery of repair peptides
Consider all three
BPC-157, TB-500, and GHK-Cu each target tissue repair through fundamentally different mechanisms operating at different biological levels. BPC-157 builds the supply lines (new blood vessels). TB-500 mobilizes the repair workforce (cell migration). GHK-Cu rebuilds the structural scaffolding (collagen, extracellular matrix). The three-compound pairing addresses repair infrastructure, repair labor, and repair materials simultaneously. No controlled study has evaluated the three-compound combination. For the two-compound pairing most commonly used in research protocols, see BPC-157 vs TB-500.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to NO System Modulation
- NO System Modulation upregulates VEGF / EGF / FGF
- VEGF / EGF / FGF connects to Blood Vessel Formation
- Blood Vessel Formation connects to Nutrient Delivery
- Tissue Repair connects to Actin Regulation
- Actin Regulation promotes Cell Migration
- Cell Migration connects to Cytokine Reduction
- Cytokine Reduction connects to Cell Arrival at Injury
BPC-157 increases growth factors (VEGF, EGF, FGF) that signal the body to build new blood vessels at the injury site.
TB-500 regulates actin, the structural protein cells use to reorganize and migrate toward damaged tissue.
GHK-Cu binds copper(II) and delivers it to tissue sites, modulating over 4,000 genes including those that build collagen.
Research Evidence
All three compounds sit at PSI's research-stage tier with primarily preclinical evidence. BPC-157 has over 200 studies with two recent human pilot trials (2024-2025). TB-500's evidence base is mostly from its parent protein Thymosin Beta-4 (1,000+ studies) rather than the fragment itself. GHK-Cu has 186 studies with topical cosmetic data in humans but zero controlled injectable trials. None has completed the clinical development needed for FDA approval. For tissue repair research, the three address complementary mechanisms; for clinical evidence, all three carry substantial gaps.
- 1.
If the research interest is GI protection, mucosal healing, or tendon repair, BPC-157 has the largest relevant preclinical evidence base, TB-500 and GHK-Cu have not been significantly studied in these contexts.
- 2.
If the research interest is skin rejuvenation or topical wound healing, GHK-Cu has the most relevant application history, supported by decades of use in cosmetic formulations, though this is topical, not systemic evidence.
- 3.
If the research interest is cardiac tissue repair or corneal healing, TB-500 (and its parent thymosin beta-4) has the most targeted research in these specific areas.
- 4.
If the research interest is broad tissue remodeling and extracellular matrix restructuring, GHK-Cu's gene expression effects are the most relevant, though primarily characterized in vitro.
Key Limitations
- •All three compounds lack completed randomized controlled trials in humans for therapeutic endpoints.
- •BPC-157's research concentration from a single group introduces replication concerns.
- •GHK-Cu's topical safety and efficacy data does not transfer to systemic applications, the route of administration fundamentally changes the pharmacological profile.
- •TB-500 is a fragment of thymosin beta-4, research on the parent protein does not automatically apply to the fragment.
- •Combination use of these peptides is widely discussed but has minimal formal research support.
- •None of these compounds has established systemic dosing, pharmacokinetics, or bioavailability data in humans.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"
Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"
Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"
Insufficient evidence
TB-500
"TB-500 is the best peptide for systemic recovery after surgery"
Plausible but unproven
"Stacking TB-500 with BPC-157 covers both local and systemic healing"
Plausible but unproven
"It healed my torn rotator cuff without surgery"
Anecdotal only
GHK-Cu
"GHK-Cu is the best anti-aging peptide for skin"
Plausible but unproven
"It regrew my hair"
Anecdotal only
"Topical is just as effective as injections"
Anecdotal only
Safety Comparison
All three have favorable preclinical safety profiles with no serious adverse events in available data. BPC-157 and TB-500 have limited human safety characterization. GHK-Cu has decades of topical cosmetic safety data but limited injectable safety information. None is FDA-approved. Compounded versions sold in research-peptide markets are not FDA-regulated and may carry purity, potency, or contamination risks.
BPC-157
Favorable safety profile in animal studies with no reported toxic effects at therapeutic doses. No significant human safety data exists. Long-term effects in humans are unknown.
TB-500
Limited safety data. Animal studies have not identified major toxicity signals, but the evidence base is narrower than BPC-157. No systematic human safety studies.
GHK-Cu
Favorable topical safety profile supported by decades of use in cosmetic formulations. Systemic (injectable) safety data is extremely limited. The copper component requires consideration, copper homeostasis disruption at high systemic doses is a theoretical concern.
What the Research Suggests
These three peptides are frequently grouped in regenerative medicine discussions, but their evidence profiles differ meaningfully. BPC-157 has the strongest overall preclinical evidence base with the broadest tissue coverage. GHK-Cu has a unique position, decades of topical use provide surface-level confidence, but systemic evidence remains preliminary. TB-500 shows promise in specific repair contexts but has the thinnest evidence foundation of the three. The common practice of combining these peptides outpaces the available research on combination protocols. PSI rates BPC-157 at Human Trials and both TB-500 and GHK-Cu at Animal Studies, reflecting the gap in evidence maturity between them.